Showing results (321-330 of 9,974) with videos related to
Sort By:
Pageof 998
Leukemia & Lymphoma|May 31, 2011
CD30: an important new target in hematologic malignanciesYehuda E Deutsch, Tamar Tadmor, Eckhard R Podack, et al.Leukemia & Lymphoma|June 9, 2011
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1Yair Herishanu, Federica Gibellini, Ndegwa Njuguna, et al.Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.Leukemia & Lymphoma|May 27, 2011
Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphomaMatteo Dell'Olio, Rosario Potito Scalzulli, Grazia Sanpaolo, et al.Leukemia & Lymphoma|June 10, 2011
Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphomaYu Xuan Koo, Daniel S W Tan, Iain B H Tan, et al.Leukemia & Lymphoma|October 14, 2011
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literatureStéphane Lepretre, Uli Jäger, Ann Janssens, et al.Leukemia & Lymphoma|October 14, 2011
Clinical implications of the molecular subtypes of diffuse large B-cell lymphomaBrian T Hill, John SweetenhamLeukemia & Lymphoma|November 8, 2011
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemiaChristoph Röllig, Christian Brandts, Shabnam Shaid, et al.Leukemia & Lymphoma|November 25, 2011
Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemiaMarie-Hélène Lafeuille, Francis Vekeman, Si-Tien Wang, et al.Leukemia & Lymphoma|November 22, 2011
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activitySteven Lane, Devinder Gill, Nigel A J McMillan, et al.Pageof 998